Entering text into the input field will update the search result below

Regeneron, Sanofi post promising data from late-stage Dupixent asthma trial

  • Regeneron Pharmaceuticals (REGN +0.4%) and Sanofi (SNY +1.0%) announce detailed results from a Phase 3 trial in which Dupixent (dupilumab) significantly reduced severe asthma attacks, and improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with

Recommended For You

About REGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
REGN--
Regeneron Pharmaceuticals, Inc.